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Abstract  
 
Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system 
(CNS) resulting in accumulating neurological disability. The disorder is more prevalent at higher 
latitudes. To investigate VDR gene variation using three intragenic restriction fragment length 
polymorphisms (Apa I, Taq I and Fok I) in an Australian MS case-control population, one hundred and 
four Australian MS patients were studied with patients classified clinically as Relapsing Remitting MS 
(RR-MS), Secondary Progressive MS (SP-MS) or Primary Progressive MS (PP-MS). Also, 104 age-, 
sex-, and ethnicity-matched controls were investigated as a comparative group. Our results show a 
significant difference of genotype distribution frequency between the case and control groups for the 
functional exon 9 VDR marker Taq I (pGen = 0.016) and interestingly, a stronger difference for the 
allelic frequency (pAll = 0.0072). The Apa I alleles were also found to be associated with MS 
(pAll = 0.04) but genotype frequencies were not significantly different from controls (pGen = 0.1). The 
Taq and Apa variants are in very strong and significant linkage disequilibrium (D′ = 0.96, P < 0.0001). 
The genotypic associations are strongest for the progressive forms of MS (SP–MS and PP–MS). Our 
results support a role for the VDR gene increasing.  
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Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the 
central nervous system (CNS) predominantly affecting young Caucasians. The 
prevalence of MS is dependent on geographical localization where very low sunlight 
exposure is directly linked to higher prevalence (Kurland, 1952). MS patients have 
low serum levels of vitamin D and this condition is reflected by higher rates of bone 
fractures occurring in MS patients as opposed to healthy individuals (Nieves et al., 
1994; Cosman et al., 1998). The vitamin D receptor (VDR) is a nuclear receptor that, 
once bound to 1,25-Dihydroxyvitamin D3 [1,25-(OH)2D3], leads to transcriptional 
suppression or activation of genes. Experiments on an MS animal model, 
experimental allergic encephalomyelitis (EAE), have shown a complete inhibition of 
disease course after the injection of the biologically active form 1,25-(OH)2D3 
(Cantorna et al., 1996). This inhibition of disease course was accompanied by 
enhanced activation of transforming growth factor beta (TGFβ), a known protective 
factor in EAE mouse models (Cantorna et al., 1998; Cautain et al., 2001) To induce 
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EAE, animals are immunized with CNS myelin antigens. If such immunization is 
preceded by 1,25-(OH)2D3 intake, this hinders EAE induction (Cantorna et al., 1996). 
Additionally, in Swiss Jim Lambert (SJL) mice, the vitamin D analog, TX527 was 
shown to decrease EAE disease severity and to postpone disease onset (Van Etten et 
al., 2003). Furthermore, studies of VDR null mice show that VDR presence is 
necessary for suppressing EAE activity (Meehan & DeLuca, 2002). Considering these 
data, VDR and its ligand show relative immunosuppressive and anti-inflammatory 
potential. VDR is expressed in peripheral leukocytes including activated T 
lymphocytes, which may explain the immunological role of VDR in suppressing 
EAE. Vitamin D decreases antigen expression by antigen-presenting cells and inhibits 
the proliferation of activated T cells and the production of proinflammatory cytokines 
such as interferon gamma (IFN-γ) (Tsoukas et al., 1984; Muller & Bendtzen, 1992, 
1996; Nataf et al., 1996). IFN-γ, a type II interferon, is found in high amounts in sera, 
plasma and lesions of patients with MS (Schrijver et al., 2004). This interferon 
activates a transduction cascade involving STAT1 factor and is detrimental in MS. 
STAT1 interaction with VDR antagonises vitamin D action (Vidal et al., 2002).  
The VDR gene is located on chromosome 12q 12–14; and, interestingly, a 
Sardinian genome-wide association study has shown a significant associative 
empirical p-value, at the 5% level, for the D12S1653 marker (marker for 12q12 
position) in MS (Coraddu et al., 2003). In addition, a second genome screen on a 
Spanish population has shown a significant association with a P-value for the same 
marker, D12S1653, of  p = 0.000001 (Goertsches et al., 2003). The D12S1653 marker 
is <3cM from the VDR gene, which contains multiple allelic variants some of which 
may lead to alterations in VDR function. Such variants may contribute to pathologies 
such as rickets or susceptibility to autoimmune diseases such as primary biliary 
cirrhosis (PBC) and autoimmune hepatitis (AH) (Peter et al., 1997; Arndt et al., 
2002). Specifically, the VDR gene contains 11 exons, with 3 exons (1a, 1b and 1c) 
found in the 5′ noncoding sequence and 8 exons (2–9) encoding the structural portion 
of the protein (Miyamoto et al., 1997). The gene contains 3 restriction fragment length 
polymorphisms defined as Taq I, Apa I, and Fok I (Figure 1). The Fok I 
polymorphism (a ACG to ATG transition) introduces an initiation codon leading to 
the addition of three amino-acids to the VDR protein. The Apa I and Taq I 
polymorphisms are located towards the 3′ end of the VDR gene more precisely within 
an intron flanked by exons 8 and 9 for Apa I and within exon 9 for Taq I. These VDR 
polymorphisms have been found to be associated with an increased risk of several 
autoimmune diseases including systemic lupus erythematosus and diabetes type 1 
(Huang et al., 2002; Skrabic et al., 2003). Interestingly, a Japanese study reported an 
association of the vitamin D receptor gene b (Bsm I) and gene a (Apa I) alleles with 
MS (Fukazawa et al., 1999; Niino et al., 2000). Prompted by these genetic findings, 
and the potential significance of the VDR in MS, we decided to investigate three 
VDR sequence polymorphisms, one from the 5′ region (Fok I) and two from the 3′ 
region (Apa I and Taq I), for their potential involvement in MS susceptibility in the 
Australian population. 
 
MATERIALS AND METHODS  
 
Subject Groups  
 
The participants of the study were unrelated and of Caucasian (Northern European) 
origin. The study protocol was approved by Griffith University’s ethics committee for 
experimentation on humans. The test groups consisted of 104 MS patients and 104 
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controls, matched for ethnicity, sex and age (+/-5 years). The MS population was 
obtained from patients from the Multiple Sclerosis Clinic at the Royal Brisbane and 
Women’s Hospital, mainly from the South East Queensland region. This case group 
consisted of 75% women and 25% men and were subdivided into three groups 
according to the clinical course: Relapsing-Remitting MS (RR-MS), Secondary 
Progressive MS (SP-MS) and Primary Progressive MS (PP-MS) with frequencies of 
40%, 36%, 24%, respectively. The control group was also obtained from the South 
East Queensland region through the Genomics Research Centre, Southport, with each 
control matched to an MS patient for the variables age (+/-5 years), sex, and ethnicity. 
All individuals gave informed consent before participating in the research. Genomic 
DNA was extracted from peripheral blood leucocytes using a standard salting-out 
protocol. 
 
 
 
Figure 1. Restriction polymorphism of VDR DNA sequence. Schematic of the VDR gene, showing the 
array of exons (squares) and relative locations of the polymorphisms tested in this study (arrows). 
 
Genotyping  
 
Three restriction fragment length polymorphisms (RFLPs) were genotyped; the Fok I 
polymorphism in the initiation codon at the 5′ end and two polymorphisms (Apa I and 
Taq I) in the 3′ region of VDR. These polymorphic regions were amplified by 
standard, unlabeled oligonucleotides followed by restriction enzyme digestion 
corresponding to each RFLP. Oligonucleotide primers used for Apa I and Taq I RFLP 
were: forward primer 5′ CAG AGC ATG GAC AGG GAG CAA G 3′; reverse 5′ 
GCA ACT CCT CAT GGG CTG AGG TCT CA 3′; and for Fok I RFLP were: 
forward 5′ GAT GCC AGC TGG CCC TGG CAC TG 3′ and reverse 5′ ATG GAA 
ACA CCT TGC TTC TTC TCC CTC 3′. For detection of the initiation codon 
polymorphism, 50–100 ng genomic DNA was amplified with 1 X polymerase chain 
reaction (PCR) buffer, 3 mM  MgCl2, 0.2 mM  each dNTP, 0.25 µM each primer and 
Taq polymerase in a 20-µL final volume on a Corbett (Sydney, Australia) PC-960 
thermocycler. Cycles consisted of a 4-min denaturation at 94ºC followed by 30 cycles 
of 94ºC for 1 min and 60ºC for 1 min then a final extension at 60ºC for 7 min. PCR 
products were digested with Fok I (1 U at 37ºC) and electrophoresed on 2% ethidium 
bromide stained agarose gels. Genotypes were denoted as FF (272 bp), Ff (272, 198, 
74 bp) or ff (198, 74 bp). For detection of the Apa I and Taq I RFLPs, amplification 
required 50–100 ng genomic DNA with PCR Premix Optimisation Buffer E 
(Epicentre Technologies, Madison, WI), 0.2 µM of each primer and Taq polymerase 
in a 25-mL reaction volume. Amplification was then performed on a Perkin Elmer 
(Foster City, CA) thermocycler with a 94ºC initial denaturation for 4 min followed by 
5 cycles of 94ºC for 45 sec, 64ºC for 60 sec and 72ºC for 2 min; and a further 25 
cycles of 94ºC for 30 sec, 64ºC for 30 sec and 72ºC for 45 sec. Following 
amplification, PCR products were digested with Apa I (2 U at 37ºC) or Taq I (2 U at 
65ºC) and electrophoresed on 2% agarose gels stained with ethidium bromide. 
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Genotypes were determined as AA (740 bp), Aa (740, 515, 225 bp) or aa (515, 225 
bp) for Apa I polymorphism; and TT (490, 245 bp), Tt (490, 290, 245, 205 bp) or tt 
(290, 245, 205 bp) for Taq I polymorphism (dominant alleles denoting absence of 
restriction site). 
 
Statistics  
 
Genotype and allele frequencies for the VDR variants were calculated from observed 
genotype counts. As a statistical control for systematic genotyping error and 
population stratification, the expected genotype proportions according to the Hardy-
Weinberg law were calculated and compared to observed genotypes. Genotype and 
allele frequencies were initially assessed for association with MS using conventional 
contingency table analyses incorporating the standard chi-squared test for 
independence. This analysis produces a χ2 statistic with one or two degrees of 
freedom and corresponding p-values for allele and genotype distributions, 
respectively. Genetic risk magnitudes (effect size) were estimated by calculating odds 
ratios (ORs) with 95% confidence intervals. Linkage disequilibrium (haplotype) 
analysis of the VDR variants was performed using the 2LD program (Zhao, 2004). 
 
RESULTS  
 
The genotype and allele frequencies for all three variants are shown in Tables I 
through III. All three genotypes for the case-control association studies conform to 
Hardy-Weinberg equilibrium (HWE) expectations (p > 0.05) in both case and control 
groups. Both genotype and allele frequencies for the Taq I variant were significantly 
different between the MS population and the control population (p = 0.016 and p = 
0.0072, respectively). A significant difference was also observed for the allelic 
distribution of the Apa I variant (p = 0.04) although the genotype distribution was not 
significantly different (p = 0.1). Neither the genotype nor the allele frequency 
distribution was significantly different between the MS and control populations for 
the Fok I variant (p > 0.2). 
 
Table I. Distribution of VDR Taq Variant (Genotype and Allele) frequencies in MS case and control 
groups 
 
       Genotypes*                    Alleles# 
Group T/T T/t t/t N (genotypes) T t 
Total MSa 27 (26%) 57 (55%) 20 (19%) 104 111 (53%) 97 (47%) 
Controlb 42 (45%) 40 (43%) 11 (12%) 93 124 (67%) 62 (33%) 
 
* genotype distribution comparison for total MS(χ2 = 8.27; p = 0.0016), #allele distribution comparison 
for total MS (χ2 = 7.22; p = 0.0072). 
aHardy-Weinberg equilibrium p = 0.302. 
bHardy-Weinber equilibrium p = 0.756. 
 
The Taq and Apa variants were found to be in very strong and significant linkage 
disequilibrium (LD) (D′ = 0.96; p < 0.0001). Neither of these two variants was in LD 
with the Fok variant. The disease-associated haplotype A-t was shown to be present in 
28% of MS cases compared to only 16% of controls. We decided to focus our 
subsequent genotypic analyses on the Taq variant because a) there is near complete 
LD between the Taq and Apa variants and b) the Taq I variant is exonic and c) this 
variant yielded the strongest independent association with MS. For the entire case 
control group, comparison of the T/t plus t/t genotypes combined against the T/T 
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genotype yielded an OR of 2.35 (95% CI: 1.29–4.27, p = 0.0048) for MS. Analysis of 
this genotype composition in the clinical subtypes (Figure 2) indicated that the 
association of the Taq I variant is stronger with the SP and PP subtypes (abbreviated 
as in the legend to Figure 2) of MS (ORs > 3; p < 0.05). 
 
Table II. Distribution of VDA Apa Variant (Genotype and Allele) frequencies in MS case and control 
groups 
 
         Genotypes*                                         Alleles# 
Group A/A A/a a/a N (genotypes) A a 
Total MSa 35 (34%) 55 (53%) 14 (13%) 104 125 (60%) 83 (40%) 
Controlb 23 (23%) 54 (54%) 23 (23%) 100 100 (50%) 100 (50%) 
 
* genotype distribution comparison for total MS(χ2 = 4.604; p = 0.01), #allele distribution comparison 
for total MS (χ2 = 4.2; p = 0.04). 
aHardy-Weinberg equilibrium p = 0.295. 
bHardy-Weinber equilibrium p = 0.424. 
 
 
Table III. Distribution of VDR Fok Variant (Genotype and Allele) frequencies in MS case and control 
groups 
 
      Genotypes*                Alleles# 
Group F/F F/f f/f N (genotypes) F f 
Total MSa 47 (48%) 40 (41%) 11 (11%) 98 134 (68%) 62 (32%) 
Controlb 34 (37%) 48 (51%) 11 (12%) 93 116 (62%) 70 (38%) 
 
* genotype distribution comparison for total MS(χ2 = 2.69; p = 0.26), #allele distribution comparison for 
total MS (χ2 = 1.52; p = 0.218). 
aHardy-Weinberg equilibrium p = 0.577. 
bHardy-Weinber equilibrium p = 0.337. 
 
  
DISCUSSION  
 
The aim of this study was to investigate three sequence polymorphisms in the VDR 
gene, one from the 5′ region and two from the 3′ region, for their involvement in MS 
susceptibility within an Australian cohort. The 3 polymorphisms investigated were 
distinguishable by Fok I, Apa I and Taq I restriction enzymes for genotyping using 
104 MS patients and 104 matched controls. Taq I is localized in exon 9 of the VDR 
gene with a T/C nucleotide substitution (ATT to ATC) although this doesn’t result in 
amino acid sequence change from codon 352 (isoleucine). However, the presence or 
absence of Taq I restriction sites has been found to be associated with variable mRNA 
stability of VDR (Morrison et al., 1994).  
In the present study, we report a strong positive association of the Taq I VDR 
marker in MS susceptibility. Both genotype and allele frequency distributions for the 
Taq I variant were significantly different between the MS and control populations. 
The allelic association was observed to be more significant than the genotypic 
association. These findings demonstrate that the rarer allele (t) is more predominant in 
MS cases than in controls. Moreover, these results suggest that those who carry the t 
allele are at least 2 times more likely to have MS than those who do not carry this 
allele. Further analysis of the clinical subtypes of MS indicates that the association 
with the Taq variant is derived primarily from the progressive clinical subtypes (SP–
MS and PP–MS) and that the risk of progressive MS is increased 3-fold for t allele 
carriers.  
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Figure 2. Odds Ratios (ORs) for the three clinical subtype groups. Relapse Remitting (RR), Secondary 
Progressive (SP), and Primary Progressive (PP), compared with controls involving the Taq1 variant for 
the T/t and t/t genotypes combined vs. T/T. The ORs for both progressive subtypes (SP, PP) are 
significantly greater than 1 (p < 0.05). 
 
The second VDR marker investigated, Apa I, was also found to be associated 
with MS. Apa I allele frequency distribution comparison was significant at the 0.05 
level with a predominant susceptibility for the A allele in MS. Interestingly, allele A 
was found associated with the progressive subtypes of MS (SP–MS and PP–MS). 
Both positive marker Taq I and Apa I variants were found to be associated with MS 
with a stronger susceptibility role for the functionally associated variant Taq I. The 
Taq I and Apa I variants were found to be in strong and very significant linkage 
disequilibrium (D′ = 0.96; p < 0.0001). This strong LD has been observed in several 
other studies (Curran et al., 1999). Therefore we suggest that the Taq I variant, 
representing a tag single nucleotide polymorphism for this haplotype, should be the 
only variant requiring genotyping in future disease- association studies of this region 
of the VDR gene. Neither of these 3′ variants was in LD with the Fok I variant. Thus, 
the LD breakdown among the VDR variants has dissociated the susceptibility 
haplotype (A-t) of the 3′ region from the 5′ Fok I variant region. 
 A similar MS case-control study, examining the Apa I marker, was previously 
undertaken by a Japanese team (Niino et al., 2000). The authors used 77 Japanese MS 
patients and 95 controls and found a significant association for Apa I allele 
distribution (p = 0.032) (Niino et al., 2001). Additionally they studied Bsm I VDR 
gene variants in MS. This other 3′ untranslated region (UTR) marker of the VDR gene 
was also found to be associated with MS, both for the allele frequency distribution (p 
= 0.014) and for the genotype frequency distribution (p = 0.049). Further data 
analysis showed that both the Bsm I and Taq I markers are also in strong LD (p < 
0.0001) (Wilkinson et al., 2000). Consequently these three markers are all in LD and 
clustered possibly as a common susceptibility haplotype (BAt) for MS. A Canadian 
team has also investigated VDR markers in MS, specifically Apa I and Taq I markers 
for the VDR gene. However, they reported no preferential transmission of any alleles 
to affected offspring using a family-based association cohort (Taq I and Apa I; p < 
0.05) (Steckley et al., 2000). The genetic heterozygosity (Hu) of the markers based on 
the genotypes of the parents was very low (Hu TaqI = 0.488 and Hu ApaI = 0.447). 
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Reliant upon high heterozygosity values, the use of bi-allelic markers for family-
based association analyses (e.g., TDT) will diminish the power to identify 
susceptibility allele transmission. 
 MS pathology is associated with the invasion of peripheral mononuclear blood 
cells into the CNS. These cells induce local inflammation in the CNS with increased 
synthesis of proinflammatory cytokines, major histocompatibility complex molecules, 
and oxidative molecules leading to CNS demyelination. Vitamin D inhibits T cell 
proliferation and IFN-γ cytokine expression (Ball et al., 1986). Vitamin D activation 
of VDR leads to the transcription of responsive elements of several genes. Certain 
VDR haplotypes could lead to the reduced expression of VDR protein and alter VDR-
induced transcription in the CNS. Vitamin D is an efficient antioxidant and plays a 
critical role in control of free radical induced tissue damage, another hallmark of MS 
pathology. VDR also has important roles affecting insulin secretion, hormone 
production including the parathyroid hormone and also on estrogen biosynthesis with 
a direct action on the aromatase gene (Haschek et al., 1978; Manolagas, 1987; 
Wilson, 1992; Kinuta et al., 2000). Of special interest, we have recently undertaken 
cDNA array-based differential display analysis of MS brain tissues versus healthy 
control brain tissue (Tajouri et al., 2003). Although our arrays did not contain a VDR 
cDNA for analysis, results showed a common pattern of activated expression of 
immunological genes in MS, and interestingly a reduced expression of the insulin 
receptor gene and insulin-related genes. Of interest, Vitamin D has been shown to 
prevent reversibly mouse models of type I diabetes (Mathieu et al., 1992). Additional 
studies show that impaired VDR functionality in mice leads to impaired insulin 
secretion (Zeitz et al., 2003). An up regulation of parathyroid hormone receptor gene 
was also found in MS from these microarray data. VDR-responsive elements are also 
found in the osteopontin gene, an early T cell activator gene found strongly expressed 
in MS brains (Chabas et al., 2001). Taken together, lower amounts of Vitamin D 
concentrations by inadequate Vitamin-D intake or ultraviolet radiation (UVR) 
exposure could contribute to the pathogenesis of MS, and additionally, presence of 
specific haplotypes for the VDR gene could increase susceptibility to MS, particularly 
the progressive forms of MS. 
 Different geographical latitudes of the Japanese, Canadian, and Australian 
populations could be a factor influencing the differences in Apa I and Taq I data 
obtained from each study. Low UVR exposure and reduced Vitamin D synthesis 
correlate with MS geographical prevalence. The MS Canadian population was pooled 
around the whole country and Canada is situated at latitudes of around 70º to 50ºN. 
The MS Japanese population studied was from the northernmost island of Japan, 
Hokkaido, and is located between 42º and 43ºN whereas South-East Queensland for 
the MS Australian population is localized at around 25º to 29ºS. It would be 
interesting to further investigate case-control studies of the Taq I VDR marker in 
extended Japanese populations, in the Canadian population and also in a Tasmanian 
Australian population (latitude of 43ºS for Hobart, Tasmania). 
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